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Objectives: Resistant hypertension (RH) is highly associated with cardiovascular 
risks. The difficulty in enrolling large numbers of study participants limits stud-
ies on treatment effects of RH. This study aims to compare the effectiveness of 
triple antihypertensive combination therapy for RH patients in Taiwan. MethOds: 
Patients who had 3 antihypertensive agents of different classes concurrently pre-
scribed in outpatient clinics with their medication possession ratio ≧ 0.7 during 
2004-2006 were identified as the RH cases from the National Health Insurance 
Research database. The 1st outpatient visit with 3 antihypertensive agents of dif-
ferent classes being prescribed was defined as the index date. Patients were further 
classified into two treatment groups according to the combination of antihyper-
tensive therapy; the A+B+C group was defined as those who received concurrent 
therapy of ACEI/ARB in combination with beta-blocker and CCB, and the A+C+D 
group was those who received ACEI/ARB together with CCB and diuretics. The 
Cox proportional regression analysis was performed to investigate the risk of 
major adverse cardiovascular events (MACE) between the two treatment groups. 
Subgroup analysis was further performed by classifying patients into those with 
or without previous history of stroke, myocardial Infarction or end stage renal 
diseases. Results: There were 13,551 patients identified as the prevalence cases 
of RH during 2004-2006. Results showed the A+C+D group had a lower risk of 
MACE when compared to the A+B+C of group (adjusted HR= 1.11; 95%CI 1.01-1.22; 
p= 0.0272). Subgroup analysis showed there was no significant difference in the risk 
of MACE between the A+B+C and the A+C+D groups either in patients with prior 
disease history (adjusted HR = 1.10; 95%CI 0.96-1.25; p= 0.1881) or without prior 
disease history (adjusted HR = 1.12; 95%CI 0.99-1.28; p= 0.0767). cOnclusiOns: 
The A+C+D combination therapy seemed to be more effective than the A+B+C 
therapy in preventing MACE among patients with RH.
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Objectives: Randomized trials have shown that blockade of beta adrener-
gic receptors leads to symptomatic improvement, reduced hospitalization and 
enhanced survival in many patients with heart failure (HF) and reduced ejec-
tion fraction. The objective of this study was to compare beta blockers for their 
efficacy in reducing mortality. MethOds: A systematic literature search for 
randomized clinical trials for use of beta blockers in HF was undertaken for the 
databases Pubmed, Embase, Biosis, Google Scholar and Cochrane. Data was col-
lected for the study type, methods, country and key findings. Extracted study 
data included study design, patient charatcertristcis and primary outcomes. A 
bayesian random effects network meta-analysis (NMA) model was developed in 
WinBUGS14. Results: We identified 830 references and found 21 randomized 
trials in 23,122 patients with 3,871 events. The treatments included in our study 
were Enalapril (E), Metoprolol (M), Atenolol (A), Bisoprolol (Bi), Bucindolol (Bu), 
Carvedilol (C), Metoprolol (M), Nebivolol (N) and placebo (P). All beta-blockers ver-
sus placebo were effective in reducing mortailty in HF and reduced ejection frac-
tion patients. Carvedilol ranked the highest with a Surface Under the Cumulative 
RAnking curve (SUCRA) score of 0.8672, Atenolol was second with score of 0.7035. 
SUCRA scores for other drugs were: Bisoprolol 0.6897, Metoprolol 0.6139, Nebivolol 
0.3704, Bucindolol 0.3519, Enalapriol 0.2635 and Placebo 0.1399. The odds ratios for 
Carvedilol and Atenolol versus placebo were 0.56 (0.43 – 0.71) and 0.54 (0.15 – 1.87), 
respectively. cOnclusiOns: Network meta-analysis shows that Carvedilol ranks 
highest among beta-blockers for reduction in mortality in patients with heart 
failure and reduced ejection fraction.
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Objectives: The National Institute for Health and Care Excellence in the United 
Kingdom (UK) recently issued guidance recommending the non-vitamin k antago-
nist oral anticoagulants (NOACs) rivaroxaban, dabigatran and apixaban for treatment 
and prevention of venous thromboembolism (VTE). An economic evaluation assess-
ing apixaban versus rivaroxaban and dabigatran found apixaban was associated 
with greater quality-adjusted life-years (QALYs) gained at a lower cost. Edoxaban, 
another NOAC, is poised to enter the (ex-United States [US]) market for the same 
indication. This analysis therefore evaluated the cost-effectiveness of apixaban 
compared to low molecular weight heparin (LMWH) followed by edoxaban from 
the perspective of the UK National Health Service. MethOds: A Markov model 
was developed to evaluate the lifetime clinical and economic impact of six-month 
treatment following a VTE event with apixaban versus LMWH/edoxaban. The model 
included the following health states: recurrent VTE, major bleed, clinically relevant 
non-major bleed, chronic thromboembolic pulmonary hypertension, and death. 
Transition rates among health states were based upon AMPLIFY and AMPLIFY-EXT 
clinical trial data, network meta-analyses, and UK life tables. Cost and utilities 
were based on published estimates. Price parity with apixaban was assumed in 
the absence of any pricing information for edoxaban. Outcomes were life-years 
gained, QALYs gained, costs estimated in 2012 British pounds, and the incremental 
cost-effectiveness ratio (ICER). Results: Six-month treatment with apixaban was 
predicted to increase life expectancy and QALYs as compared to LMWH/edoxaban 
over a lifetime horizon. When these treatments were priced at parity, apixaban 
was associated with cost-savings due to avoided bleeds and higher cost of LMWH. 
Dominance was maintained even when edoxaban was priced at an 18% discount 
disease and obesity, as well as between sHTG and diabetes and acute pancreati-
tis. Patients with HTG received treatment with statins, fibrates, and omega-3 for-
mulations, including omega-3 ethyl esters and omega-3 fatty acids. Combination 
therapy was typically more effective at reducing TG levels than monotherapy. 
Economic data were reported only for sHTG patients in the United States (US) 
with annual direct costs from $8,000 -$9,000. Patients with TG levels > 17 mmol/L 
observed a marked increase in the total all-cause medical and pharmacy costs, 
which reached $12,642/year. Prescription omega-3 ethyl esters were cost-effective 
in the US based on a simulation model estimating $47,000/quality-adjusted life-year 
using a threshold of $50,000. Only two identified studies reported patient-centered 
outcomes. cOnclusiOns: High HTG prevalence in various regions indicates dis-
ease burden is not effectively managed by current therapies and suggests a need for 
new treatments. Treating HTG and associated comorbidities results in a substantial 
economic burden. Further research is needed on the patient-centered burden of 
HTG and the economic impact of this disease, specifically in non-US locations and 
patients with TG levels ≥ 2.26 and < 5.6 mmol/L.
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Objectives: Atrial fibrillation is the most common arrhythmia, affecting more 
than 4.5 million people in Europe. Owing to recent introduction of novel oral anti-
coagulant (NOACs) treatments in Germany, there is a need to generate real-world 
evidence on the profiles of patients with NVAF prescribed with such therapies. This 
study aimed to describe demographic and clinical characteristics of patients with 
NVAF newly prescribed NOACs in Germany. MethOds: Retrospective cohort study 
of patients with NVAF who were newly prescribed with NOACs (index prescription) 
between December 2012 and October 2014, using German primary care data from 
IMS Disease Analyzer. We calculated summary statistics of demographic and clini-
cal characteristics in each NOAC therapy group. Results: Overall, 2,678 patients 
initiated apixaban, 2,696 dabigatran, and 9,562 rivaroxaban in the study period. At 
time of index NOAC initiation, mean age was 75.9 years (standard deviation 10.0; 
interquartile range 71-83) for apixaban, 74.5 (SD 10.3; IQR 69-82) for dabigatran, and 
74.7 (SD 10.4; IQR 69-82) for rivaroxaban. Across all NOAC therapies, around half 
were men and approximately 80% lived in West Germany. Patients on apixaban 
had higher rates of stroke risk factors such as hypertension (88.2% vs. 86.4% and 
85.4% for dabigatran and rivaroxaban, respectively); vascular diseases (61.3% vs. 
57.2% and 58.5%); and congestive heart failure (43.5% vs. 39.6% and 40.9%); and 
higher rate of bleeding history (30.0% vs. 27.1% and 27.8%). cOnclusiOns: In 
routine clinical practice in Germany, patients newly treated with NOACs were 
elderly and frequently had comorbidities of cardiovascular importance such 
as hypertension and vascular diseases. Patients on apixaban had higher rates 
of stroke risk factors and bleeding history, which are likely to impact treat-
ment patterns and outcomes observed in this population. Future comparative 
effectiveness research across NOACs should account for channeling in patient 
profiles.
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Objectives: To review trends in pulmonary embolism-related discharges and 
understand sociodemographic and seasonal factors correlated with a PE diagnosis 
among hospitalized Spanish patients. MethOds: Using hospital discharge data 
from the Encuesta de Morbilidad Hospitalaria we analyzed trends in PE-related 
hospital discharges in Spanish hospitals from 2008 to 2011. PE was defined based on 
principal diagnosis ICD-9 codes 41511 (Iatrogenic pulmonary embolism and infarc-
tion), 41512 (septic pulmonary embolism), 41513 (saddle embolus of pulmonary 
artery), and 41519 (other pulmonary embolism and infarction). The principal diag-
nosis was established to be the primary reason the patient was hospitalized. Results 
were stratified by age, sex, province and season of the year. We used log-binomial 
and logistic regression models to evaluate the relationship between these char-
acteristics and a diagnosis of PE. Results: Of the 18,317,000 hospital admissions 
over the 4-year period, 56,600 (0.31%) were primarily PE-related. The proportion of 
PE diagnosis of all hospitalizations remained steady, ranging from 0.28%- 0.34%. PE 
risk was similar among males and females; risk ratio (RR) 1.03 95% CI (1.04-1.07). 
PE-related hospitalizations increased with age however, rates were higher in men 
65 years and younger than their female counterparts and higher in women 70 and 
older than their male counterparts. The greatest change (30% increase) in diagnosis 
from 2008-2011 was among 40-59 year olds and people over 80. We found a seasonal 
variation in PE diagnosis, with lowest rates of diagnosis in April to July in both 
males and females, over the 4-year period. PE hospitalization rates were two times 
higher in the northern than southern regions RR 1.82(1.76-1.88). cOnclusiOns: 
Age, gender, geographic location and month of the year were correlated with diag-
nosis of PE among hospitalized Spanish patients. A future area of research is to 
clarify these relationships and determine possible interventions to reduce PE in 
these populations.
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